Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

Now Viewing

EP: 1.Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

EP: 2.Ponatinib Dose-Ranging Data in Chronic-Phase CML

EP: 3.Treatment Considerations for Ponatinib in Patients With CML

EP: 4.Olverembatinib in Patients with Pretreated/Refractory CML

EP: 5.Potential Role of Olverembatinib in CML

EP: 6.ASCEMBL: Recent Data Updates for Asciminib in CML

EP: 7.Clinical Applications for Asciminib in CML

EP: 8.OPTIC Trial: 3-Year Data Update in CML

EP: 9.Treatment Updates and Key Highlights in Multiple Myeloma and CML

Transcript:

Judy Schreiber, PhD, RN: Good evening and welcome to Cancer Network’s Face-Off. Today we’re going to focus on multiple myeloma [MM] and chronic myeloid leukemia [CML]. My name is Judy Schreiber and I’m today’s host. Our program, Face-Off, is a series that’s a little different than any of the educational events you’ve seen in the past. But make no mistake, Face-Off is educational at its core; [however,] it’s designed to be fun.

What makes it…unique and different from other educational events is [that] it’s not just the presentation, but it’s [so much] more. It’s a competition. Tonight we have 2 teams, 1 from the Karmanos Cancer Institute [Detroit, Michigan,] captained by Dr Andrew Kin, and the Cleveland Clinic Cancer Center team, captained by Dr Jack Khouri.

They are not just presenting data to you, but they’re presenting to and at each other. So how does it work? The Karmanos Cancer Institute team will lead off, and they will be presenting a study to the Cleveland Clinic team, after which the Karmanos team will have the opportunity to challenge the Cleveland Clinic’s team…[…and] vice versa. One team presents the other team challenges, and there’s a back-and- forth question there.

Then presenters should make sure that their presentation presents a certain level of enthusiasm or levity. At the end of each of the abstract sessions, being presented, there’ll be some questions and answers that you in the audience can answer. So the answers will be used to score how each team did, and the team, with the most correct answers, will go home as the winner with trophies, ribbons, and bragging rights.

At this time I’d like to introduce the 2 captains, Dr Kin. If you can introduce your team, followed by Dr Khouri.

Andrew Kin, MD: Thank you, Judy. I’m Andrew Kin. I’m part of the myeloma team at the Karmanos Cancer Institute. Our team today for the myeloma side is myself as well as Dr Jeffrey Zonder, professor at Karmanos Cancer Institute, and Dr Craig Cole, who is my myeloma expert, who we’re fortunate enough to have at our regional McLaren Lansing Karmanos partnership. For the CML side, we have Dr Jay Yang and Dr Charles Schiffer, both of whom are experts in leukemia and CML, specifically.

Jack Khouri, MD: Hi, everyone. I’m Jack Khouri with the Cleveland Clinic [Cleveland, Ohio] with the myeloma and bone marrow transplant programs. I’ll be talking about myeloma today, and I have Dr Faiz Anwer with me. We’ll also be talking about the topic of CML, for that we have Dr John Molina and Dr Moaath Mustafa Ali with the leukemia program here at the clinic. It’s good to be here with all of you.

Judy Schreiber, PhD, RN: Thank you for those introductions.

Transcript is AI-generated and edited for clarity and readability.